천식 스페이서 시장 : 시장 인사이트, 경쟁 환경 및 시장 예측(-2030년)

ASTHMA SPACERS MARKET BY PRODUCT TYPE (AEROCHAMBER, OPTICHAMBER, VOLUMATIC, AND INSPIREASE), BY DISTRIBUTION CHANNEL (HOSPITAL & RETAIL PHARMACY, E-COMMERCE, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO RISE AT A SIGNIFICANT CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF ASTHMA AND OTHER RESPIRATORY DISORDERS AND SURGING EXPOSURE TO DUST, SMOKING, FUMES, AMONG OTHERS ACROSS THE GLOBE

The global asthma spacers market was valued at USD 1.36 billion in 2023, growing at a CAGR of 5.82% during the forecast period from 2024 to 2030 to reach USD 1.90 billion by 2030. The asthma spacers market is observing an optimistic market growth due to the factors such as the rising prevalence of various respiratory disorder such as asthma, COPD, bronchitis, lung cancer, and others. Further, the surging geriatric population and increasing exposure to dust, fumes, airborne chemicals, smoking, and others will also drive the market of asthma spacers market in the given forecast period. Additionally, the increasing launches of technologically advanced products and the presence of key players in the market will also spur the demand of asthma spacers in the market in the given forecast period. Therefore, the market for asthma spacers is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

ASTHMA SPACERS MARKET DYNAMICS:

One of the key aspect for driving the asthma spacers market is the rising prevalence of various respiratory disorders such asthma, COPD, tuberculosis, and others globally. For instance, according to the World Health Organization (WHO) 2022, it was estimated in 2019 that worldwide around 262 million people were suffering from asthma in 2019. Additionally, the Asthma and Lung UK Organization 2022, had also stated that in UK, about 5.4 million people suffered from asthma disorder, in 2022. The number accounts to about one in every 12 adults and one in every 11 children.

Further, the rising cases of pneumonia which is a type of acute respiratory infection affecting the lungs is another factor impacting the growth of asthma spacer market. As per the WHO 2022, worldwide pneumonia caused 14% of all deaths of children under 5 years old, killing 740,180 children in 2019. The above-mentioned figures illustrate the increasing incidence of various respiratory disorders across the globe, which would lead to an increase in demand for its treatment and management devices such as nebulizers, respiratory inhalers, and others. The increasing demand of the above-mentioned devices will increase the demand of asthma spacer as these spacers are used with the devices to administer the dose of the drug easily to the patient, thereby driving the growth of the asthma spacer market.

The growing geriatric population prone to the development of respiratory disorders will also lead to an increase in the demand for asthma spacers, during the forecast period (2022-2028).

Additionally, according to the WHO 2022, it is expected that by 2030, out of six at least one person will have his/her age 60 years or above. As per the same source, by 2050, the number of people having age 60 years or above will be around 2.1 billion. Also, as per above mentioned source, the number of people having age 80 years or above is expected to reach 426 million between 2020 and 2050. The increasing age owing to the weak immune system and structural changes in the spine, muscles, and ribs over time makes aged people susceptible to the development of multiple respiratory diseases such as asthma, chronic bronchitis, bronchiectasis, and chronic obstructive pulmonary disease (COPD) among others. Thus, increasing ageing population at the risk of developing respiratory diseases will lead to an increase in the demand for asthma spacers, causing an overall increase in the market growth of asthma spacers in the forecast period.

Therefore, the factors stated above collectively will drive the overall asthma spacers market during the forecast period from 2024-2030.

However, high cost of the device, lack of professional guidance to patients and practitioners regarding a product or device usage, and others may prove to be challenging factors for asthma spacer's market growth.

The COVID- 19 pandemic had a moderate impact on the market growth of asthma spacers during the initial few months owing to the lockdown impositions, border closures, and others leading to the disruption in the manufacturing, supply, import, export, and other related activities of the asthma spacers market. However, during the latter half of the pandemic, the asthma spacer market started to recover owing to the resumption of activities across industries including the healthcare sector. Additionally, the asthma spacer market also saw increase in product demand owing to the rise in number of cases of COVID-19 infection. The asthma spacers were used with respiratory inhalers in order to cure the chest congestion in COVID-19 patients, ultimately increasing its demand. Thus, the above stated factors increased the demand of asthma spacers during the pandemic and it anticipated to do the same in the forecast period of 2022 - 2028.

ASTHMA SPACERS MARKET SEGMENT ANALYSIS:

Asthma Spacers Market by Product Type (Aerochamber, Optichamber, Volumatic, and Inspirease), Distribution Channel (Hospital & Retail Pharmacy, E-Commerce, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the asthma spacers market, the aerochamber segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of respiratory disorders and due to the wider advantage circle of the segment as compared to the other type.

Additionally, aerochambers are gaining popularity due to their improved ability to deliver medicine in a slow and regulated manner. The aerochambers spacers reduces the risk of side effects, direct contamination such as oral thrush, and reduces chances of anthroponoses diseases. Also, the aerochambers assists delivery of medicine to the small airways in the lungs, thereby increasing the medicine's effectiveness.

Additionally, the portable size of the spacers, efficiency and convenience make the aerochambers a desirable method for inhalation treatment, especially in geriatric patients.

Further, presence of advanced products in the market will help in driving the market of aerochamber spacers in the upcoming years. For instance, AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (VHC) of Trudell Medical International, is one of the most progressed spacer or chamber. It helps patients inhale metered dosed inhalation medications (MDI) correctly. It is used for the patients who may have difficulty with the coordination and control involved in using MDIs correctly.

Therefore, owing to the advantages and applications associated with the aerochambers, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global asthma spacers market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ASTHMA SPACERS MARKET:

Among all the regions, the North America is expected to dominate the global asthma spacers in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the increasing prevalence of asthma and other respiratory disorders in the region, the increasing exposure to smoking, dust, fumes, and the presence of key market players in the region are factors which acts as a supportive factor for the North America asthma spacers market growth.

As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020, including 4.2 million children. This equals about 1 in every 13 people. Further, according to the National Center for Health Statistics 2020-2022, percentage of chronic obstructive pulmonary disorders (COPD), emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

Also, according to the statistics provided by Lung Association 2020 - 2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022. Also, the data published by Statics Canada 2022, specified that nearly 57,300 people were suffering from COPD in the year 2020.

Further, the air quality can be an underrated factor for various respiratory diseases. According to the WHO 2022, an estimated 15,300 premature deaths were reported in 2022, in Canada as a result of air pollution. The health effects of air pollution range in severity from irritated airways and dizziness, worsening of asthma or to causing lung cancer or COPD. The increasing exposure to air pollution will increase the prevalence of disorders such as asthma, COPD, and others, thereby increasing the demand of treatment and management devices like respiratory inhalers. The asthma spacer or inhalation chamber is attached to the inhalers in order to administer adequate amount of the dose to the patient. Thus, the increasing prevalence of respiratory disorders will propel the demand of inhalers, ultimately driving the market of asthma spacers.

Additionally, the increasing ease of access to modern devices, presence of key players in the region, increasing healthcare expenditure, and others will also spur the market of asthma spacers in the upcoming years.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the asthma spacers market.

ASTHMA SPACERS MARKET KEY PLAYERS:

Some of the key market players operating in the asthma spacers market includes PARI GmbH, Koninklijke Philips N.V., HAAG-STREIT GROUP, Cipla Inc., Trudell Medical International, Monaghan, Laboratoire ProtecSom, Koo Medical Equipment., AGPMED, Rossmax International Ltd., Teleflex, GSK Plc., Lupin Pharmaceuticals, Inc., Air Liquide Healthcare, GaleMed Corporation., SunMed, ARMSTRONG MEDICAL, DTF Medical, Visiomed, Allergan, Inc., and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ASTHMA SPACERS MARKET:

In May 2022 Monaghan Medical Corporation (Monaghan) and Captis announced that their agreement to a three-year contract creating a partnership between two industry leaders. The sole source agreement recognizes the value of Monaghan's patient outcome evidence and gold standard medical devices in in two categories medication delivery and Oscillatory Positive Expiratory Pressure/Positive Airway Pressure devices with Captis' desire to drive process efficiencies and value driven healthcare spending.

In April 2020, Adherium Limited, a leader in digital inhaled device adherence, remote monitoring, and data management solutions, has signed a heads of terms sales agreement with Monaghan Medical Corporation, the United States subsidiary of Trudell Medical Limited. Monaghan has an established and comprehensive sales team working across the United States supporting AeroChamber, Aerobika and AeroEclipse device commercialization.

KEY TAKEAWAYS FROM THE ASTHMA SPACERS MARKET REPORT STUDY

• Market size analysis for current asthma spacers market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the asthma spacers market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global asthma spacers market.
• Various opportunities available for the other competitor in the asthma spacers market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current asthma spacers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for asthma spacers market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ASTHMA SPACERS MARKET REPORT STUDY

• Asthma spacers products providers
• Research organizations and consulting companies
• Asthma Spacers -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in asthma spacers
• Various end users who want to know more about the asthma spacers market and latest technological developments in the asthma spacers market.

FREQUENTLY ASKED QUESTIONS FOR ASTHMA SPACERS MARKET:

1. What is an asthma spacers?

The asthma spacers, also known as inhalation chamber, are an external device that increases inhalation and actuation to improve drug delivery. Spacers help in administrating the right amount of medicine to the lungs when used along with the metered dose inhaler (MDI). The use of an asthma spacer helps to reduce medicine waste and limits the occurrence of dose-related side effects.

2. What is the global market for Asthma Spacers?

The global asthma spacers market was valued at USD 1.36 billion in 2023, growing at a CAGR of 5.82% during the forecast period from 2024 to 2030 to reach USD 1.90 billion by 2030.

3. What are the drivers for global asthma spacers market?

The asthma spacers market is witnessing a positive market growth owing to the factors such as the rising prevalence of as the rising prevalence of respiratory disorders, growing geriatric population, and the technological advancements across the globe.

4. Who are the key players operating in the global asthma spacers market?

Some of the key market players operating in the asthma spacers market includes PARI GmbH, Koninklijke Philips N.V., HAAG-STREIT GROUP, Cipla Inc., Trudell Medical International, Monaghan, Laboratoire ProtecSom, Koo Medical Equipment., AGPMED, Rossmax International Ltd., Teleflex, GSK Plc., Lupin Pharmaceuticals, Inc., Air Liquide Healthcare, GaleMed Corporation., SunMed, ARMSTRONG MEDICAL, DTF Medical, Visiomed, Allergan, Inc., and others.

5. Which region has the highest share in asthma spacers market?

Among all the regions, North America is estimated to hold the significant revenue share in the global asthma spacers market. This can be ascribed to the increasing prevalence of asthma and other respiratory disorders in the region, the increasing exposure to smoking, dust, fumes, and the presence of key market players in the region are factors which acts as a supportive factor for the North America asthma spacers market growth.

Table of Contents

1. Asthma Spacers Market Report Introduction

2. Asthma Spacers Market Executive Summary

• 2.1 Scope of the Study
• 2.2 Market at Glance
• 2.3 Competitive Assessment
• 2.4 Financial Benchmarking

3. Regulatory Analysis

• 3.1 The United States
• 3.2 Europe
• 3.3 Japan
• 3.4 China

4. Asthma Spacers Market Key Factors Analysis

• 4.1 Asthma Spacers Market Drivers
  • 4.1.1 The rising prevalence of respiratory disorders across the globe
  • 4.1.2 Augmented levels of air pollution globally
  • 4.1.3 New product launches and strategic activities by major players
• 4.2 Asthma Spacers Market Restraints and Challenges
  • 4.2.1 High cost of the device
  • 4.2.2 Lack of professional guidance to patients and practitioners regarding a product or device usage
• 4.3 Asthma Spacers Market Opportunities
  • 4.3.1 Increasing awareness amongst patients about the benefits of spacers

5. Asthma Spacers Market Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers
• 5.2 Bargaining Power of Consumers
• 5.3 Threat of New Entrants
• 5.4 Threat of Substitutes
• 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Asthma Spacers Market

7. Asthma Spacers Market Layout

• 7.1 By Product Type
  • 7.1.1 Aerochamber
  • 7.1.2 Optichamber
  • 7.1.3 Volumatic
  • 7.1.4 Inspirease
• 7.2 By Distribution Channel
  • 7.2.1 Hospital & Retail Pharmacy
  • 7.2.2 E-Commerce
  • 7.2.3 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Asthma Spacers Market in USD million (2021-2030)
    • 7.3.1.2 Canada Asthma Spacers Market in USD million (2021-2030)
    • 7.3.1.3 Mexico Asthma Spacers Market in USD million (2021-2030)
  • 7.3.2 Europe
    • 7.3.2.1 France Asthma Spacers Market in USD million (2021-2030)
    • 7.3.2.2 Germany Asthma Spacers Market in USD million (2021-2030)
    • 7.3.2.3 United Kingdom Asthma Spacers Market in USD million (2021-2030)
    • 7.3.2.4 Italy Asthma Spacers Market in USD million (2021-2030)
    • 7.3.2.5 Spain Asthma Spacers Market in USD million (2021-2030)
    • 7.3.2.6 Rest of Europe Asthma Spacers Market in USD million (2021-2030)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Asthma Spacers Market in USD million (2021-2030)
    • 7.3.3.2 Japan Asthma Spacers Market in USD million (2021-2030)
    • 7.3.3.3 India Asthma Spacers Market in USD million (2021-2030)
    • 7.3.3.4 Australia Asthma Spacers Market in USD million (2021-2030)
    • 7.3.3.5 South Korea Asthma Spacers Market in USD million (2021-2030)
    • 7.3.3.6 Rest of Asia Pacific Asthma Spacers Market in USD million (2021-2030)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1. Middle East Asthma Spacers Market in USD million (2021-2030)
    • 7.3.4.2 Africa Asthma Spacers Market in USD million (2021-2030)
    • 7.3.4.3 South America Asthma Spacers Market in USD million (2021-2030)

8. Asthma Spacers Market Global Company Share Analysis - Key 3-5 Companies

9. Asthma Spacers Market Company and Product Profiles

• 9.1 PARI GmbH
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2 Koninklijke Philips N.V.,
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3 HAAG-STREIT GROUP
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4 Cipla Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4 Product Listing
  • 9.4.5. Entropy
• 9.5 Trudell Medical International
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4 Product Listing
  • 9.5.5. Entropy
• 9.6 Monaghan
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4 Product Listing
  • 9.6.5. Entropy
• 9.7 Laboratoire ProtecSom
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4 Product Listing
  • 9.7.5. Entropy
• 9.8 Koo Medical Equipment.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4 Product Listing
  • 9.8.5. Entropy
• 9.9 AGPMED
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4 Product Listing
  • 9.9.5. Entropy
• 9.10 Rossmax International Ltd.
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4 Product Listing
  • 9.10.5. Entropy
• 9.11 Teleflex
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4 Product Listing
  • 9.11.5. Entropy
• 9.12 GSK Plc.
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4 Product Listing
  • 9.12.5. Entropy
• 9.13 Lupin Pharmaceuticals, Inc.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4 Product Listing
  • 9.13.5. Entropy
• 9.14 Air Liquide Healthcare
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4 Product Listing
  • 9.14.5. Entropy
• 9.15 GaleMed Corporation.
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4 Product Listing
  • 9.15.5. Entropy
• 9.16 SunMed
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4 Product Listing
  • 9.16.5. Entropy
• 9.17 ARMSTRONG MEDICAL
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4 Product Listing
  • 9.17.5. Entropy
• 9.18 DTF Medical
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4 Product Listing
  • 9.18.5. Entropy
• 9.19 Visiomed
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4 Product Listing
  • 9.19.5. Entropy
• 9.20 Allergan, Inc.
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4 Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us